NO800460L - Fremgangsmaate ved fremstilling av teofyllinderivat - Google Patents

Fremgangsmaate ved fremstilling av teofyllinderivat

Info

Publication number: NO800460L
Authority: NO; Norway
Prior art keywords: theophylline; zinc; aminophylline; complex; salt
Prior art date: 1979-02-21

Application number

NO800460A

Other languages

English (en)

Norwegian (no)

Inventor

Eli Shefter

Francis X Smith

Mark J Gardner

Original Assignee

Research Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-02-21

Filing date

1980-02-20

Publication date

1980-08-22

1980-02-20 Application filed by Research Corp filed Critical Research Corp

1980-08-22 Publication of NO800460L publication Critical patent/NO800460L/no

Links

ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims description 139
238000000034 method Methods 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 8
229960000278 theophylline Drugs 0.000 claims description 70
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 23
229960003556 aminophylline Drugs 0.000 claims description 22
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 19
229910052725 zinc Inorganic materials 0.000 claims description 19
239000011701 zinc Substances 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 17
-1 diamine salt Chemical class 0.000 claims description 16
238000006243 chemical reaction Methods 0.000 claims description 10
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 7
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 4
229910021529 ammonia Inorganic materials 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical group [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims 2
239000012736 aqueous medium Substances 0.000 claims 1
201000006747 infectious mononucleosis Diseases 0.000 claims 1
235000005074 zinc chloride Nutrition 0.000 claims 1
239000011592 zinc chloride Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 14
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 9
239000002552 dosage form Substances 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
239000003826 tablet Substances 0.000 description 9
150000003751 zinc Chemical class 0.000 description 9
230000000694 effects Effects 0.000 description 8
210000002784 stomach Anatomy 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
150000001412 amines Chemical class 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
208000009079 Bronchial Spasm Diseases 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
235000019640 taste Nutrition 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010000059 abdominal discomfort Diseases 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
235000019658 bitter taste Nutrition 0.000 description 3
230000036765 blood level Effects 0.000 description 3
239000007910 chewable tablet Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000000047 product Substances 0.000 description 3
210000003296 saliva Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
230000009967 tasteless effect Effects 0.000 description 3
208000014181 Bronchial disease Diseases 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000003929 acidic solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
125000003916 ethylene diamine group Chemical group 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001934 delay Effects 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000036647 reaction Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960004016 sucrose syrup Drugs 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

NO800460A 1979-02-21 1980-02-20 Fremgangsmaate ved fremstilling av teofyllinderivat NO800460L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1326679A	1979-02-21	1979-02-21

Publications (1)

Publication Number	Publication Date
NO800460L true NO800460L (no)	1980-08-22

Family

ID=21759081

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO800460A NO800460L (no)	1979-02-21	1980-02-20	Fremgangsmaate ved fremstilling av teofyllinderivat

Country Status (4)

Country	Link
EP (1)	EP0015684A1 (da)
JP (1)	JPS55147294A (da)
DK (1)	DK74880A (da)
NO (1)	NO800460L (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69715756T2 (de)	1996-08-20	2003-02-06	Sumitomo Rubber Industries Ltd., Kobe	Verfahren und Vorrichtung zur Herstellung eines radialen Luftreifens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4073907A (en) *	1976-06-01	1978-02-14	Abbott Laboratories	Stabilized aminophylline solution and process therefor

1980
- 1980-02-20 NO NO800460A patent/NO800460L/no unknown
- 1980-02-21 JP JP1976280A patent/JPS55147294A/ja active Pending
- 1980-02-21 DK DK74880A patent/DK74880A/da unknown
- 1980-02-21 EP EP80300508A patent/EP0015684A1/en not_active Withdrawn

Also Published As

Publication number	Publication date
DK74880A (da)	1980-08-22
EP0015684A1 (en)	1980-09-17
JPS55147294A (en)	1980-11-17

Publication	Publication Date	Title
CA1040532A (en)	1978-10-17	Process for producing solid bismuth-containing pharmaceutical compositions
US4368197A (en)	1983-01-11	Zinc aminophylline and its use in the treatment of bronchospasms
US4859704A (en)	1989-08-22	Water soluble ibuprofen compositions and methods of making them
US4956386A (en)	1990-09-11	Pharmaceutical compositions and process for their preparation
PT88448B (pt)	1992-10-30	Processo para a preparacao de composicoes farmaceuticas antiprotozoarias contendo azitromicina ou um seu derivado
DK162840B (da)	1991-12-16	Zink(ii)-komplekser af substituerede 3-hydroxypyroner eller 3-hydroxypyridoner, anvendelse af disse samt farmaceutiske praeparater indeholdende disse
NZ216978A (en)	1990-01-29	Crystalline monohydrates and sodium salt monohydrates of guanine derivates and pharmaceutical compositions
KR870000322B1 (ko)	1987-02-27	1-에틸-6-플루오로-1,4-디히드로-4-옥소-7-(1-피페라지닐)-1,8-나프티리딘-3-카르복실산, 3/2수화물의 제법.
US5723453A (en)	1998-03-03	Stabilized, water-soluble aspirin composition
JPS6121528B2 (da)	1986-05-27
NO138772B (no)	1978-07-31	Fremgangsmaate ved fremstilling av kornorienterte staalplater eller -baand
US4880835A (en)	1989-11-14	Oral liquid pharmaceutical compositions of sulindac
NO800460L (no)	1980-08-22	Fremgangsmaate ved fremstilling av teofyllinderivat
US5064857A (en)	1991-11-12	Liquid bismuth containing medicinal product, process for producing it and its use
WO2021047528A1 (zh)	2021-03-18	一个烟醇醚衍生物的马来酸盐及其晶型和应用
RU2589507C1 (ru)	2016-07-10	Средство на основе сухого экстракта пустырника и способ его получения
JPS6121529B2 (da)	1986-05-27
US2940898A (en)	1960-06-14	Aluminum salt antacid compositions and method of using same
US4243679A (en)	1981-01-06	S-(3-Methyl-2-butenyl)cysteine
DK149804B (da)	1986-10-06	Fremgangsmaade til fremstilling af et stabilt cholin-salicylat-carboxy-c1-4alkylcellulose-metalkompleks
US3914433A (en)	1975-10-21	Method of relieving the discomfort of pharyngitis
US3491135A (en)	1970-01-20	Pamoates of (3-cyclohexyl-3-hydroxy-3-phenylpropyl) triethylammonium having unobjectionable flavors
JPH0435476B2 (da)	1992-06-11
RU2611194C2 (ru)	2017-02-21	Лекарственное средство на основе тетраметилтетраазобициклооктандиона и способ его получения
US2678296A (en)	1954-05-11	Nu-benzyl-betachloropropionamide anticonvulsant article of manufacture